Resources Repository
-
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
Technology Assessment | Health/Medicine | Global | Policy/Regulation | Probability/Bayes | Test Performance | Infectious Diseases | Health Systems | Government/Law | North America -
ArticlePublication 2018Comparing Cost-per-QALYs Gained to Cost-per-DALYs Averted
The authors examined 6,438 cost-per-QALY and 543 cost-per-DALY studies published through 2016 using two databases, …
The authors examined 6,438 cost-per-QALY and 543 cost-per-DALY studies published through 2016 using two databases, the Tufts Medical Center CEA Registry (cost-per-QALY gained studies), and the Global Cost-Effectiveness Analysis (GHCEA) Registry (cost-per-DALY averted studies). Study characteristics that were analyzed included intervention type, sponsor, country, primary disease, and number of CEAs versus disease burden estimates for major conditions. The authors report that cost-per-QALY studies were most often about pharmaceuticals or interventions in high-income countries while cost-per-DALY…
Evidence Synthesis | Health/Medicine | Global | Policy/Regulation | Cost-Effectiveness Analysis -
ReportPublication 2019Top 10 Health Economics and Outcomes Research Trends
As governments and other payers struggle with provision of the best possible health outcomes at …
As governments and other payers struggle with provision of the best possible health outcomes at affordable costs, the field of health economics and outcomes research (HEOR) has experienced rapid growth. The International Society for Pharmacoeconomics Outcomes Research (ISPOR) produced the ISPOR 2019 Top 10 HEOR Trends which serves to outline the top 10 that the Society members identified that will be the most impactful during 2019. Development of this report included a comprehensive review and…
Health Outcomes | Health/Medicine | Global | Policy/Regulation | Social Determinants | Health Systems | Global Governance | Science/Technology -
ReportPublication 2016Economics of Tobacco and Tobacco Control
This report examines the current research and evidence base surrounding the economics of tobacco control—including tobacco …
This report examines the current research and evidence base surrounding the economics of tobacco control—including tobacco use, tobacco growing, manufacturing and trade, tobacco product taxes and prices, and tobacco control policies and other interventions to reduce tobacco use and its consequences. The report was co-produced by the National Cancer Institute and the World Health Organization and is intended to inform tobacco prevention and control programs and policies in countries around the world. There are 17 chapters which can be…
Costing Methods | Health/Medicine | Global | Policy/Regulation | Benefit-Cost Analysis | Chronic Disease/Risk | Food/Agriculture | Government/Law -
ArticlePublication 2016Reproductive, Maternal, Newborn, and Child Health: Key Messages from DCP3
As part of the Disease Control Priorities, Third Edition, the World Bank has published a …
As part of the Disease Control Priorities, Third Edition, the World Bank has published a volume on Reproductive, Maternal, Newborn and Child Health that identifies essential cost-effective health interventions that can be scaled-up now to reduce maternal, newborn and child deaths, and stillbirths. This article summarizes the key findings and estimates the impact and cost of expanded implementation of these interventions. Scaling up all preventive and therapeutic health interventions in these integrated packages from current…
Costing Methods | Health/Medicine | Global | Maternal/Reproductive Health | Cost-Effectiveness Analysis | Child/Nutrition | Health Systems -
ArticlePublication 2016Costs and Benefits of Integrated RMNCH
This chapter assesses the costs and benefits of delivering a set of integrated reproductive, maternal, …
This chapter assesses the costs and benefits of delivering a set of integrated reproductive, maternal, newborn and child health interventions in countries with high child and maternal mortality to demonstrate that very high returns can be achieved through this investment and to underscore the importance of an accurate assessment of those returns. This includes the full range of costs involved in delivering integrated care and the full range of benefits that flow from the interventions.…
Costing Methods | Health/Medicine | Global | Maternal/Reproductive Health | Priority Setting/Ethics | Child/Nutrition | Health Systems | Economics/Finance -
ArticlePublication 2016Using Cost-Effectiveness Evidence to Inform Health Service Provision
This article discusses three challenges of using cost-effectiveness thresholds to inform whether a third-party payer …
This article discusses three challenges of using cost-effectiveness thresholds to inform whether a third-party payer will fund a particular service. First, how is the appropriate cost-effectiveness threshold - or threshold range - to be determined? (And should there be a single threshold or multiple thresholds?) Second, how can the valuation of health benefits be refined to better capture the value of treatments to patients and to the economy as a whole? Third, how should a…
Evidence Synthesis | Health/Medicine | Global | Policy/Regulation | Priority Setting/Ethics | Cost-Effectiveness Analysis